ICOSL增强腺病毒载体疫苗诱导针对非糖基化MUC1抗原的双极Th17/Th1 T细胞应答
该研究在识别人MUC1为自身抗原的转基因小鼠模型中评估ICOSL增强靶向非糖基化MUC1肽抗原的腺病毒载体疫苗的免疫原性。疫苗接种打破免疫耐受并诱导MUC1特异性免疫,ICOSL增强后诱导双极Th17/Th1效应表型,且Th17极化持久,并显著增强MUC1特异性IgG抗体。
要点
- ICOSL增强的腺病毒疫苗诱导MUC1特异性双极Th17/Th1效应表型。
- CD4+ T细胞中IL-17A和RORγt升高持续至初次免疫后10个月。
- ICOSL增强显著提高MUC1特异性IgG抗体应答。
核心结论
- ICOSL支持体内诱导持久、抗原特异性的Th17/Th1介导免疫,建立增强CD4+ T细胞介导抗肿瘤免疫的疫苗接种平台。
研究设计与样本
- 在识别人MUC1为自身抗原的转基因小鼠模型中评估ICOSL增强靶向非糖基化MUC1肽抗原的腺病毒载体疫苗的免疫原性。
主要发现
- 疫苗接种打破转基因小鼠对MUC1的免疫耐受,诱导强效MUC1特异性免疫。
- ICOSL增强诱导双极Th17/Th1效应表型,CD4+ T细胞中MUC1特异性IL-17A产生和RORγt表达增加,而CD8+ T细胞主要表达IFNγ/IL-2和T-bet。
- ICOSL增强后建立的Th17细胞极化高度持久,初次免疫后10个月CD4+ T细胞中IL-17A和RORγt水平仍升高。
- ICOSL增强显著提高免疫后MUC1特异性IgG抗体。
- ICOSL信号显著影响CD4+ T细胞表型,改变免疫后转录因子和效应功能调节因子的基因表达,但未改变CD8+ T细胞的转录谱,仅影响基因表达幅度而非分布。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cellular immunity established via immunotherapy holds the potential to eliminate solid tumors. Yet, cancer vaccines have failed to induce tumor-reactive T cells of sufficient quality to control disease. The inducible T cell costimulator (ICOS) pathway has been implicated in both the selective induction of immunity over tolerance as well as licensing of IL-17-polarized cellular immunity. Herein, we evaluated the ability of ICOS ligand (ICOSL) to augment the immunogenicity of adenoviral-based vaccination targeting the unglycosylated MUC1 peptide antigen. Vaccination disrupted immunotolerance in a transgenic mouse model recognizing human MUC1 as a self-antigen, inducing robust MUC1-specific immunity. Augmenting vaccination with ICOSL induced a bipolar Th17/Th1 effector profile, marked by increased MUC1-specific IL-17A production and RORγt expression in CD4+ but not CD8+ T cells which predominantly expressed IFNγ/IL-2 and T-bet. The polarization and maintenance of Th17 cells established following ICOSL augmented vaccination was highly durable, with elevated IL-17A and RORγt levels detected in CD4+ T cells up to 10 months after initial immunization. Furthermore, provision of ICOSL significantly enhanced MUC1-specific IgG antibody in response to immunization. ICOSL signaling dramatically influenced CD4+ T cell phenotype, altering gene expression of transcription factors and regulators of effector function following immunization. Interestingly, ICOSL augmentation failed to alter the transcriptional profile of CD8+ T cells following immunization, affecting the magnitude, but not distribution, of gene expression. Collectively, ICOSL supports the induction of durable, antigen-specific Th17/Th1-mediated immunity in vivo, establishing a vaccination platform to enhance CD4+ T cell-mediated antitumor immunity and providing a crucial component of an effective cancer vaccine.
引用
- Carrell RK, Stanton RA, Ethier SP, et al. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. Vaccine. 2018. PMID: 30219366. doi:10.1016/j.vaccine.2018.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。